Health Innovation Hubs in MENA: From National Health Strategy to Health Economy

Health innovation hubs are emerging as the practical mechanism to turn national health targets across the Middle East and North Africa into deployable patient solutions and exportable businesses, argues Daren Wilson, co‑founder and senior partner at HealthSeed. Countries in the region already publish measurable commitments — Saudi Arabia targeting a life expectancy of 80 by 2030 (reported at 79.7 in 2025), the UAE aiming to be among the world’s top 15 health systems for quality by 2031, Qatar targeting life expectancy of 82.6 and a 36% reduction in noncommunicable disease deaths by 2030, and Tunisia seeking a one‑third reduction in premature deaths from chronic disease by 2030 — but most lack an operating model that links those targets to hospital wards and to scaleable companies.

"A health innovation hub is a public‑private partnership, anchored in a hospital, that turns clinical challenges named by clinicians into solutions developed with companies and researchers and then brought to market," Wilson writes, defining the model that sits at the centre of the region’s proposed health‑economy strategy.

Wilson lays out the rationale: four structural pressures make hubs necessary. Noncommunicable diseases account for 66% of deaths in the WHO Eastern Mediterranean Region; diabetes affects around 85 million adults in the Region (an adult prevalence of 17.6%), and the number of adults with diabetes in the IDF MENA region rose from 17.0 million in 2000 to 84.7 million in 2024, with 162.6 million projected by 2050. Ageing populations will expand the 65+ cohort from 20.8 million in 2020 to 71.5 million by 2050. Meanwhile the WHO projects a global shortfall of 10 million health workers by 2030, with the Eastern Mediterranean Region accounting for more than 20% of that gap. Finally, the average lag between research and routine clinical practice remains long — often cited as 17 years — a gap hubs are designed to shorten.

• Clinical anchor: Hubs begin with clinician‑named problems and validate solutions in routine care, increasing adoption potential.
• Pre‑agreed rules: Partners — hospitals, companies and researchers — co‑develop under intellectual property and compensation terms set before development.
• Commercialisation: Successful projects are converted into companies that serve patients locally and export abroad, returning value to the public system.

Wilson highlights international precedents that illustrate the model. Helsinki University Hospital’s CleverHealth Network, founded in 2017, has run nine co‑development projects with around 20 industry partners; one home dialysis project moved 20 additional patients to home care and delivered EUR 476,200 a year in hospital savings, later commercialised with Fujitsu. Switzerland’s national model — Switzerland Innovation — provides a lighter, catalytic public role through a network of innovation parks and affiliated locations.

The hub approach also frames a regional data and discovery advantage: by keeping patient data under national control while connecting hubs across borders, countries could leverage the region’s genetic diversity for global drug discovery and AI healthcare workstreams. HealthSeed’s analysis groups development into five sector tracks — MedTech, HealthTech, AI Healthcare, AI Drug Discovery, and BioTech — reflecting the range of projects hubs can incubate.

Outlook: health innovation hubs, if adopted at scale, offer a route from stated national ambitions to tangible patient outcomes and local health economies. By anchoring development in hospitals, setting commercial rules up front, and validating innovations in routine care, hubs aim to shorten adoption lags, create revenue streams for public providers, and retain capital and talent in the region while opening export pathways for successful companies.